Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices 6915 

approval of the information collection 

described in Section A. The Federal 

Register notice that solicited public 

comment on the information collection 

for a period of 60 days was published 

on June 1, 2020 at 85 FR 33189. 

A. Overview of Information Collection 

Title of Information Collection: 

Mortgage Record Change. 

OMB Approval Number: 2502–0422. 

Type of Request: Extension. 

Form Number: 92080 (FHA 

Connection). 

Description of the need for the 

information and proposed use: 

Servicing of insured mortgages must be 

performed by a mortgagee that is 

approved by HUD to service insured 

mortgages. The Mortgage Record Change 

information is used by FHA-approved 

mortgagees to comply with HUD 

requirements for reporting the sale of a 

mortgage between investors and/or the 

transfer of the mortgage servicing 

responsibility, as appropriate. 

Respondents (i.e. affected public): 

Not-for-profit institutions. 

Estimated Number of Respondents: 

10,000. 

Estimated Number of Responses: 

3,500,000. 

Frequency of Response: On occasion 

at sale or transfer. 

Average Hours per Response: .1. 

Total Estimated Burdens: 350,000. 

B. Solicitation of Public Comment 

This notice is soliciting comments 

from members of the public and affected 

parties concerning the collection of 

information described in Section A on 

the following: 

(1) Whether the proposed collection 

of information is necessary for the 

proper performance of the functions of 

the agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information; 

(3) Ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and 

(4) Ways to minimize the burden of 

the collection of information on those 

who are to respond; including through 

the use of appropriate automated 

collection techniques or other forms of 

information technology, e.g., permitting 

electronic submission of responses. 

(5) ways to minimize the burden of 

the collection of information on those 

who are to respond, including the use 

of automated collection techniques or 

other forms of information technology. 

HUD encourages interested parties to 

submit comments in response to these 

questions. 

C. Authority 

Section 2 of the Paperwork Reduction 

Act of 1995, 44 U.S.C. 3507. 

Colette Pollard, 

Department Reports Management Officer, 

Office of the Chief Information Officer. 

[FR Doc. 2021–01520 Filed 1–22–21; 8:45 am] 

BILLING CODE 4210–67–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–7034–N–05; OMB Control 

No.: 2502–0524] 

30-Day Notice of Proposed Information 

Collection: Home Equity Conversion 

Mortgage (HECM) Insurance 

Application for the Origination of 

Reverse Mortgages and Related 

Documents 

AGENCY: Office of the Chief Information 

Officer, HUD. 

ACTION: Notice. 

SUMMARY: HUD has submitted the 

proposed information collection 

requirement described below to the 

Office of Management and Budget 

(OMB) for review, in accordance with 

the Paperwork Reduction Act. The 

purpose of this notice is to allow for an 

additional 30 days of public comment. 

DATES: Comments Due Date: February 

24, 2021. 

ADDRESSES: Interested persons are 

invited to submit comments regarding 

this proposal. Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

Start Printed Page 15501PRAMain. Find 

this particular information collection by 

selecting ‘‘Currently under 30-day 

Review—Open for Public Comments’’ or 

by using the search function. 

FOR FURTHER INFORMATION CONTACT: 

Colette Pollard, Reports Management 

Officer, QDAM, Department of Housing 

and Urban Development, 451 7th Street 

SW, Washington, DC 20410; email 

Colette Pollard at Colette.Pollard@

hud.gov or telephone 202–402–3400. 

Persons with hearing or speech 

impairments may access this number 

through TTY by calling the toll-free 

Federal Relay Service at (800) 877–8339. 

This is not a toll-free number. Copies of 

available documents submitted to OMB 

may be obtained from Ms. Pollard. 

SUPPLEMENTARY INFORMATION: This 

notice informs the public that HUD has 

submitted to OMB a request for 

approval of the information collection 

described in Section A. The Federal 

Register notice that solicited public 

comment on the information collection 

for a period of 60 days was published 

on September 17, 2020 at 85 FR 58068. 

A. Overview of Information Collection 

Title of Information Collection: Home 

Equity Conversion Mortgage (HECM) 

Insurance Application for the 

Origination of Reverse Mortgages and 

Related Documents. 

OMB Approval Number: 2502–0524. 

Type of Request: Revision of currently 

approved collection. 

Form Number: HUD–92901, HUD– 

92902, HUD–92051, HUD–92561, HUD– 

92800.5b, HUD–92900–A, HUD–92300, 

HUD–1, HUD–1a, Fannie Mae (FNMA)- 

1009, FNMA–1025, FNMA–1003, 

FNMA–1004, FNMA–1004c, FNMA– 

1073, HUD–92541, HUD–92544, 

NPMA–99A, NPMA–99B 

Description of the need for the 

information and proposed use: The 

Home Equity Conversion Mortgage 

(HECM) program is the Federal Housing 

Administration’s (FHA) reverse 

mortgage program that enables seniors 

who have equity in their homes to 

withdraw a portion of the accumulated 

equity. The intent of the HECM Program 

is to ease the financial burden on 

elderly homeowners facing increased 

health, housing, and subsistence costs at 

a time of reduced income. The currently 

approved information collection is 

necessary to screen mortgage insurance 

applications to protect the FHA 

insurance fund and the interests of 

consumers and potential borrowers. 

Specific forms and related documents 

are needed to determine the eligibility 

of the borrower and proposed mortgage 

transaction for FHA’s insurance 

endorsement. The model HECM 

Adjustable Rate Note has been revised 

to align with FHA’s transition from the 

London InterBank Offered Rate (LIBOR) 

index to the Secured Overnight 

Financing Rate (SOFR) index, which 

includes, but is not limited to, new 

definitions and replacement index 

language for future adjustable interest 

rate index transition events. 

HUD also proposes to strengthen the 

HECM for Purchase property eligibility 

requirements by requiring inspection 

documentation for newly built 

properties that will serve as collateral 

for HECM financing. Currently, the 

HECM for Purchase program requires 

mortgagees to submit a Certificate of 

Occupancy, or its equivalent, as 

evidence that the property is complete 

and habitable as a condition of FHA 

insurance. In the near future, 

mortgagees may be required to complete 

and submit the following forms to FHA: 

(1) Form HUD–92541, Builder’s 


jbell on DSKJLSW7X2PROD with NOTICES
6916 Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices 

Certification of Plans, Specifications, 

and Site; (2) Form HUD–92544, 

Warranty of Completion of 

Construction; (3) Form HUD–NPMA– 

99–A, Subterranean Termite Protection 

Builder’s Guarantee; and (4) Form 

HUD–NPMA–99–B, New Construction 

Subterranean Termite Service Record. 

These forms are currently required by 

FHA for maximum financing for FHA’s 

Title II Single Family forward mortgage 

programs and will align both the reverse 

and forward mortgage programs to 

ensure the property meet’s FHA’s 

minimum property standards while 

ensuring the home is safe, sound, and 

secure for the HECM borrower. 

Respondents (i.e., affected public): 

Business or other for profit. 

Estimated Number of Respondents: 

2,375. 

Estimated Number of Responses: 

59,375. 

Frequency of Response: Occasionally. 

Average Hours per Response: 2.54 

hours. 

Total Estimated Burdens: 116,398.75. 

B. Solicitation of Public Comment 

This notice is soliciting comments 

from members of the public and affected 

parties concerning the collection of 

information described in Section A on 

the following: 

(1) Whether the proposed collection 

of information is necessary for the 

proper performance of the functions of 

the agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information; 

(3) Ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and 

(4) Ways to minimize the burden of 

the collection of information on those 

who are to respond: Including through 

the use of appropriate automated 

collection techniques or other forms of 

information technology, e.g., permitting 

electronic submission of responses. 

(5) Ways to minimize the burden of 

the collection of information on those 

who are to respond, including the use 

of automated collection techniques or 

other forms of information technology. 

HUD encourages interested parties to 

submit comments in response to the 

proposed changes. 

Authority: Section 3507 of the Paperwork 

Reduction Act of 1995, 44 U.S.C. Chapter 35. 

Colette Pollard, 

Department Reports Management Officer, 

Office of the Chief Information Officer. 

[FR Doc. 2021–01515 Filed 1–22–21; 8:45 am] 

BILLING CODE 4210–67–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1238] 

Certain Plant-Derived Recombinant 

Human Serum Albumins (‘‘rHSA’’) and 

Products Containing Same; Notice of 

Institution of Investigation 

AGENCY: International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that a 

complaint was filed with the U.S. 

International Trade Commission on 

December 16, 2020, under section 337 of 

the Tariff Act of 1930, as amended, on 

behalf of Ventria Bioscience Inc. of 

Junction City, Kansas. Supplements to 

the complaint were filed on December 

16, and 22, 2020. The complaint, as 

supplemented, alleges violations of 

section 337 based upon the importation 

into the United States, the sale for 

importation, and the sale within the 

United States after importation of 

certain plant-derived recombinant 

human serum albumins (‘‘rHSA’’) and 

products containing same by reason of 

infringement of certain claims of U.S. 

Patent No. 10,618,951 (‘‘the ’951 

patent’’); and U.S. Patent No. 8,609,416 

(‘‘the ’416 patent’’). The complaint 

further alleges that an industry in the 

United States exists as required by the 

applicable Federal Statute. The 

complaint also alleges violations of 

section 337 based on the importation 

into the United States, or in the sale of, 

certain plant-derived recombinant 

human serum albumins (‘‘rHSA’’) and 

products containing same by reason of 

false designation of origin, the threat or 

effect of which is to destroy or 

substantially injure an industry in the 

United States. 

The complainant requests that the 

Commission institute an investigation 

and, after the investigation, issue a 

limited exclusion order and cease and 

desist orders. 

ADDRESSES: The complaint, except for 

any confidential information contained 

therein, may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. For help 

accessing EDIS, please email 

EDIS3Help@usitc.gov. Hearing impaired 

individuals are advised that information 

on this matter can be obtained by 

contacting the Commission’s TDD 

terminal on (202) 205–1810. Persons 

with mobility impairments who will 

need special assistance in gaining access 

to the Commission should contact the 

Office of the Secretary at (202) 205– 

2000. General information concerning 

the Commission may also be obtained 

by accessing its internet server at 

https://www.usitc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Pathenia M. Proctor, The Office of 

Unfair Import Investigations, U.S. 

International Trade Commission, 

telephone (202) 205–2560. 

SUPPLEMENTARY INFORMATION: 

Authority: The authority for 

institution of this investigation is 

contained in section 337 of the Tariff 

Act of 1930, as amended, 19 U.S.C. 

1337, and in section 210.10 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10 (2020). 

Scope of Investigation: Having 

considered the complaint, the U.S. 

International Trade Commission, on 

January 14, 2021, ordered that— 

(1) Pursuant to subsection (b) of 

section 337 of the Tariff Act of 1930, as 

amended, an investigation be instituted 

to determine: 

(a) Whether there is a violation of 

subsection (a)(1)(B) of section 337 in the 

importation into the United States, the 

sale for importation, or the sale within 

the United States after importation of 

certain products identified in paragraph 

(2) by reason of infringement of one or 

more of claims 1–3 and 11–13 of the 

’951 patent and claims 1–3, 5–7, 10, 12, 

18–20, and 22–25 of the ’416 patent; and 

whether an industry in the United 

States exists as required by subsection 

(a)(2) of section 337; and 

(b) Whether there is a violation of 

subsection (a)(1)(A) of section 337 in the 

importation into the United States, or in 

the sale of, certain products identified 

in paragraph (2) by reason of false 

designation of origin. 

(2) Pursuant to section 210.10(b)(1) of 

the Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10(b)(1), the 

plain language description of the 

accused products or category of accused 

products, which defines the scope of the 

investigation, is: Plant-derived 

recombinant human serum albumins 

(‘‘rHSA’’) and products containing the 

same, such as lyophilized powders and 

liquid suspensions primarily containing 

rHSA along with naturally-occurring 

plant expression by-products, such as 

plant heat shock proteins and/or plant 

fatty acids, as well as cell culture media 

supplements formulated with such 

rHSA products. 

(3) For the purpose of the 

investigation so instituted, the following 

are hereby named as parties upon which 

this notice of investigation shall be 

served: 

(a) The complainant is: Ventria 

Bioscience Inc., 2718 Industrial Drive, 

Junction City, Kansas 66441. 


jbell on DSKJLSW7X2PROD with NOTICES